Failure to Obtain Consent and Educate on Psychotropic Medications
Summary
The facility failed to ensure residents or their representatives were informed of the risks versus benefits, alternative treatments, and consent requirements before psychotropic medications were administered or changed for four sampled residents. The report identified this issue for residents 3, 6, 21, and 32, and documented that no consent forms or related education were found in the records for multiple antipsychotic, antidepressant, and anti-anxiety medications. The deficiency was identified through record review, staff interviews, and policy review. Resident 21 had severe cognitive impairment with diagnoses including Alzheimer’s disease, dementia with agitation and behavioral disturbance, and neurocognitive disorder with Lewy Bodies. He had orders for temazepam, trazodone, lorazepam Intensol oral concentrate, lorazepam, Risperdal, and sertraline, but the record did not show that his representative was informed of the risks versus benefits, alternative treatments, or consent for these medications. The chart also showed a 1/30/26 order note to discontinue lorazepam, but active orders still reflected the PRN lorazepam doses, and there was no documentation that the lorazepam orders were discontinued. The resident did not have a diagnosis of depression despite being ordered sertraline. Resident 6 had severe cognitive impairment and did not have diagnoses of schizophrenia, bipolar disorder, anxiety, depression, or a severe behavioral disorder. He had orders for sertraline for depression, Haldol PRN for agitation, and Seroquel for agitation, but the record did not show that his representative was informed of the risks versus benefits, alternative treatments, or consent for these medications. The behaviors treated by Seroquel were not identified, and there was no diagnosis for use documented for that medication. Resident 3 had moderately impaired cognition and diagnoses of anxiety disorder and dementia with behavioral disturbance. She had orders for alprazolam PRN, escitalopram, haloperidol PRN, Seroquel at bedtime, and trazodone at bedtime, but there was no documentation that she or her representative was informed of the risks versus benefits, alternative treatments, or consent for these medications. Resident 32 had intact cognition and a diagnosis of dementia with agitation. She had orders for lorazepam PRN, scheduled lorazepam, mirtazapine, quetiapine, and olanzapine, but the record did not show that she or her representative was informed of the risks versus benefits, alternative treatments, or consent for these medications. Staff interviews confirmed the facility did not have a process in place to review risks versus benefits, discuss alternatives, or obtain consent before starting or changing psychotropic medications, and the DON and CEO acknowledged that consent forms were not being completed and that appropriate diagnoses were not documented for some medications.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release August 26, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.